510(k) device
Neu Platform
Neuhealth Digital , Ltd. · Transducer, Tremor (GYD, Class II) · First FDA decision Apr 25, 2025, newest Apr 25, 2025Essential tremorParkinson's disease
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
9
Naming "Neu"
MAUDE reports
124
Brand "Neu", since 2015
PubMed studies
11,251
Mentioning "Neu"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Neu Platform
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Neu PlatformThird-party review510(k)
K250153 · Decided Apr 25, 2025 · 94 days after receipt
Device type: Transducer, Tremor (GYD) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Positron Emission Tomography (FDG) and Other Neuroimaging Devices for Suspected DementiaNational analysisReview closedCAG-00088RUpdated Sep 21, 2026
- Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative DiseaseNational analysisReview closedCAG-00431RUpdated Sep 16, 2026
- Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative DiseaseNational analysisReview closedCAG-00431NUpdated Sep 16, 2026
- Pneumatic Compression Pumps for Venous InsufficiencyNational analysisReview closedCAG-00075NUpdated Sep 15, 2026
- Neuromuscular Electrical Stimulation (NMES) for Spinal Cord InjuryNational analysisReview closedCAG-00153RUpdated Sep 15, 2026
- Human Chorionic Gonadotropin (Addition of ICD-9-CM Code 158.9, Malignant Neoplasm of Peritoneum, Unspecified)Coding analysisReview closedCAG-00372NUpdated Sep 14, 2026
- Diabetic Peripheral Neuropathy with Loss of Protective Sensation (LOPS)National analysisReview closedCAG-00059NUpdated Jul 6, 2026
- Lung Volume Reduction Surgery (Reduction Pneumoplasty)National determinationOn the books240.1Updated Mar 3, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Neu", any status and sponsor, newest update first.
- Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderPivotal-lookingRecruiting
National Institute of Mental Health (NIMH)NIH
NCT03065335 · 150 participants (planned) · Start May 25, 2017 · Primary completion Jan 1, 2027
Device: Cobot TS MV robotic arm for TMS; NeurOptics PLRTM-30000 Pupillometer · For: Healthy Volunteer; Major Depressive Disorder; Depression
Sites: Bethesda, Maryland
8 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Neu", and for the whole product code for context.
This brand
124 reports: 41 malfunction, 83 injury, 0 death
Whole product code GYD
3 reports: 3 malfunction, 0 injury, 0 death
Newest reports for this brand
2028492-2026-03481 · Received Aug 24, 2026 · Event dated Jul 29, 2026
Device type: System, Test, Her-2/Neu, Ihc (MVC)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Neu"[tiab]. The summary above synthesizes these.
- HER-2/neu-targeting gene therapy--a review.
Hung MC, Matin A, Zhang Y, et al. · Gene · 1995Research Support, U.S. Gov't, P.H.S., Review
- HER2/neu-directed therapy for biliary tract cancer.
Javle M, Churi C, Kang HC, et al. · J Hematol Oncol · 2015Research Support, Non-U.S. Gov't
- HER-2/neu expression in glioblastoma multiforme.
Haynik DM, Roma AA, Prayson RA · Appl Immunohistochem Mol Morphol · 2007
- HER2/neu testing in primary colorectal carcinoma.
Ingold Heppner B, Behrens HM, Balschun K, et al. · Br J Cancer · 2014Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Cancer Vaccines Co-Targeting HER2/Neu and IGF1R.
De Giovanni C, Landuzzi L, Palladini A, et al. · Cancers (Basel) · 2019
- Egr-1 is required for neu/HER2-induced mammary tumors.
Oh S, Kim H, Nam K, et al. · Cell Signal · 2018Research Support, Non-U.S. Gov't
- Comparison of Her2/Neu Oncoprotein in Serum and Tissue Samples in Women with Breast Cancer.
Pokhrel R, Yadav BK, Sharma N, et al. · Asian Pac J Cancer Prev · 2022Comparative Study
- Review of the Role of HER2/neu in Colorectal Carcinomas.
Achalla LSV, Shinde RK, Jogdand S, et al. · Cureus · 2022Review
- HER-2/neu expression in germ cell tumours.
Soule S, Baldridge L, Kirkpatrick K, et al. · J Clin Pathol · 2002Research Support, U.S. Gov't, P.H.S.
- Her-2/neu and breast cancer.
Kaptain S, Tan LK, Chen B · Diagn Mol Pathol · 2001Review
- Her-2/neu gene amplification and its correlation with other prognostic factors in Iranian breast cancer patients.
Isaee S, Zahraei Z, Poursina D, et al. · Mol Biol Rep · 2024
- Strategies to target HER2/neu overexpression for cancer therapy.
Chen JS, Lan K, Hung MC · Drug Resist Updat · 2003Research Support, U.S. Gov't, P.H.S., Review
Other devices of this type
Also filed under product code GYD.
- Personal Kinetigraph (PKG) System Gen 2 PlusGkc Manufacturing Pty, Ltd. · 510(k) 2022
- Kneu Platform (V2)Kneu Health Digital , Ltd. · 510(k) 2026
- Empatica Health Monitoring Platform for Parkinson's Disease MonitoringEmpatica S.r.l. · 510(k) 2026
- Sine Monitoring Parkinsons Disease Tremor Dyskinesia Apple Watch (SMPDTDAW)Nordic Kinetics AB · 510(k) 2026
- NeuroRPMNew Touch Digital, Inc. · 510(k) 2023
- Parky AppH2o Bilisim Yazilim · 510(k) 2022
- Rune Labs Tremor Transducer SystemRune Labs, Inc. · 510(k) 2022
- KinesiaCleveland Medical Devices, Inc. · 510(k) 2007
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.